Indivior (LON:INDV) Earns Buy Rating from Jefferies Financial Group

Jefferies Financial Group restated their buy rating on shares of Indivior (LON:INDV) in a research note issued to investors on Tuesday, MarketBeat.com reports. The brokerage currently has a GBX 1,800 ($22.88) price target on the specialty pharmaceutical company’s stock.

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 1,500 ($19.07) price target on shares of Indivior in a report on Thursday, September 5th.

Indivior Stock Performance

LON:INDV opened at GBX 931 ($11.84) on Tuesday. The stock has a 50-day moving average price of GBX 768.84 and a 200 day moving average price of GBX 923.78. The stock has a market capitalization of £1.20 billion, a P/E ratio of -1,155.41, a P/E/G ratio of -5.57 and a beta of 0.19. Indivior has a 12-month low of GBX 554.50 ($7.05) and a 12-month high of GBX 1,770 ($22.50). The company has a current ratio of 0.85, a quick ratio of 1.52 and a debt-to-equity ratio of 2,790.00.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.